Description du projet
Un avenir sans frottement pour les cathéters
Les cathéters sont des dispositifs médicaux indispensables, mais ils sont souvent confrontés à un problème de taille: le frottement superficiel. Cela compromet à la fois la sécurité et le confort du patient. Dans ce contexte, le projet ExtruLub, financé par l’UE, propose une solution pour transformer les performances des cathéters sans altérer leurs propriétés de base. Plus précisément, la technologie d’extrusion innovante du projet réduit le frottement superficiel, génère des surfaces antimicrobiennes et antithrombogènes, et garantit une sécurité maximale pour les patients. Les fabricants de dispositifs obtiendront un avantage concurrentiel sur le marché des cathéters, en bénéficiant d’une véritable différenciation de leurs produits et en ayant la possibilité de s’approprier une plus grande part de marché. En passant d’une production allégée à une production par lots, la technologie permettra de réaliser d’importantes économies. Globalement, cette nouvelle technologie devrait générer des millions d’euros de revenus et créer de nouveaux emplois.
Objectif
ExtruLubTM is an innovative, disruptive extrusion technology applicable across a range of polymer resins, which can change the surface of a catheter without affecting core device properties. The technology fits in the component sub-supply market with an initial global market of €564 mn applicable across all catheter markets, the latter estimated to reach $42.5 bn globally by 2020. From a functional perspective, it has the ability to reduce surface friction, generate protective antimicrobial & antithrombogenic surfaces, passing these benefits and profile reduction to catheters. This functional enhancement safeguards patient safety & commands genuine product differentiation for the device manufacturer, enabling market share. From an economic perspective it facilitates a change from lean to batch manufacturing realising cost containment. For example, an independent study showed ExtruLubTM, employed in the cardiology sector, would reduce costs for the OEM (e.g. Boston Scientific, Medtronic etc.) by 51 %, realising savings for them of ca. €3 mn p.a in one product. DiaNia Technologies will drive the optimisation & advancement of successful Phase 1 results through to commercialisation of ExtruLubTM into selected devices, engaging with a number of successful, leading MedTech companies. In doing so we will utilise direct links with MNCs at the early development phase of their new products. DNT will be taking an export led approach, exploiting the experience of our business development team & board members in expanding our component subsupply business in the MedTech industry. The positive effects of this project include increase in revenues to over €26 MN & employees numbers reaching 38 in YR 5 through the successful rollout of ExtruLubTM Technology.
Champ scientifique
- medical and health sciencesclinical medicineangiologyvascular diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural scienceschemical sciencespolymer sciences
- medical and health sciencesclinical medicinecardiology
- medical and health sciencesmedical biotechnologyimplants
Mots‑clés
Programme(s)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
H91 Y682 Galway
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.